Aytu BioPharma (AYTU) to Release Quarterly Earnings on Wednesday

Aytu BioPharma (NASDAQ:AYTU) will likely be announcing its Q1 2026 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $17.9220 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earningresults page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 4:30 PM ET.

Aytu BioPharma (NASDAQ:AYTU) last announced its quarterly earnings data on Tuesday, September 23rd. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.24). The firm had revenue of $15.14 million for the quarter, compared to analysts’ expectations of $18.06 million. Aytu BioPharma had a negative net margin of 20.43% and a positive return on equity of 13.77%.

Aytu BioPharma Stock Performance

Shares of Aytu BioPharma stock opened at $2.13 on Wednesday. The company has a current ratio of 1.26, a quick ratio of 1.07 and a debt-to-equity ratio of 0.57. The business has a fifty day simple moving average of $2.25 and a two-hundred day simple moving average of $2.08. Aytu BioPharma has a 12 month low of $0.95 and a 12 month high of $2.82. The firm has a market capitalization of $21.70 million, a P/E ratio of -0.76 and a beta of 0.25.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Zacks Research cut Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research note on Friday, October 10th. Wall Street Zen cut Aytu BioPharma from a “buy” rating to a “hold” rating in a research note on Friday, September 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Tuesday, October 14th. Maxim Group cut their target price on Aytu BioPharma from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, September 25th. Finally, Ascendiant Capital Markets increased their target price on Aytu BioPharma from $12.00 to $12.50 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Three analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $9.17.

Aytu BioPharma Company Profile

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.